Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer

Update Mammakarzinom 2019 Teil 4 – diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien für Patientinnen mit frühem Mammakarzinom

Authors
Florian Schütz¹, Peter A. Fasching², Manfred Welslau³, Andreas D. Hartkopf⁴, Achim Wöckel⁵, Michael P. Lux⁶, Wolfgang Janni⁷, Johannes Ettl⁸, Diana Lüftner⁹, Erik Belleville¹⁰, Hans-Christian Kolberg¹¹, Friedrich Overkamp¹², Florin-Andrei Taran¹, Sara Y. Brucker⁴, Markus Wallwiener¹, Hans Tesch¹³, Tanja N. Fehm¹⁴, Andreas Schneeweiss¹⁵, Volkmar Müller¹⁶

Affiliations
1 Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany
2 Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
3 Onkologie Aschaffenburg, Aschaffenburg, Germany
4 Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
5 Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
6 Kooperatives Brustzentrum Paderborn, Klinik für Gynäkologie und Geburtshilfe Frauenklinik St. Louise, Paderborn, St. Josef-Krankenhaus, Salzkotten, Germany
7 Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
8 Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
9 Charité University Hospital, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany
10 ClinSol GmbH & Co KG, Würzburg, Germany
11 Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
12 OncoConsult Hamburg GmbH, Hamburg, Germany
13 Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany
14 Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
15 National Center for Tumor Diseases, Division Gynecologic Oncology, University Hospital Heidelberg, Heidelberg, Germany
16 Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany

Key words
breast cancer, adjuvant, neoadjuvant, chemotherapy, antihormone therapy, multigene tests

Schlüsselwörter
Mammakarzinom, adjuvant, neoadjuvant, Chemotherapie, Antihormontherapie, Multigentests

received 24.7. 2019
revised 4.8. 2019
accepted 22.8. 2019

Bibliography
DOI https://doi.org/10.1055/a-1001-9925
Geburtsh Frauenheilk 2019; 79: 1079–1089 © Georg Thieme Verlag KG Stuttgart · New York | ISSN 0016-5751

Correspondence
Peter A. Fasching, MD
Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen EMN, Friedrich Alexander University of Erlangen-Nuremberg
Universitätsstraße 21–23, 91054 Erlangen, Germany
peter.fasching@uk-erlangen.de

Deutsche Version unter:
https://doi.org/10.1055/a-1001-9925
ABSTRACT

The further development of therapies for women with early breast cancer is progressing far more slowly than in the case of patients with advanced breast cancer and is additionally delayed compared to developments in metastatic breast cancer. Nonetheless, significant advancements have been able to be recorded recently. This review summarises the latest developments in view of the most recent publications and professional conferences. For hormone-receptor-positive patients, new aspects for the duration of anthormone therapy and with regard to the benefits of multigene tests have been published. In the case of HER2-positive patients, the value of post-neoadjuvant therapy and de-escalation of the therapy is discussed. In patients with triple-negative breast cancer, there is a question of whether the knowledge of the biological background of a homologous recombination deficiency (HRD) helps develop new therapies for this subtype. In particular the “use” of a *BRCA1/2* mutation or the biological characteristic HRD as a potential motive for therapy plays a role here in specifying the significance of platinum therapy and therapy with PARP inhibitors.

Introduction

In recent years, a number of studies have been published on patients with breast cancer which represent particular challenges for patients as well as physicians. In the case of patients with early breast cancer, it is discussed whether multigene tests can help identify those patients in whom chemotherapy can definitively be avoided and vice-versa, whether patients with a poor prognosis can also benefit from chemotherapy. In particular, the assumption of costs by the health insurance companies for such tests has been the subject of controversy in discussions in recent years. Moreover, particularly in the case of HER2-positive breast cancer, opportunities have been created by modern, so-called post-neoadjuvant study concepts to offer patients not only effective therapies for which standard treatment has not yet been sufficient but also to better understand the molecular mechanisms of resistance of a neoadjuvant therapy. The latest study results, including against the background of the current conferences such as the conference of the American Society of Clinical Oncology, ASCO in 2019 are summarised below.

Prevention and Risk Factors

One of the most challenging undertakings in personalised medicine is undoubtedly individualised prevention for each patient. While prevention is one of the most important principles of medicine to prevent damage from occurring in the first place, it is difficult to identify those individuals for whom certain measures are useful.

With regard to genetic risk factors, approx. 200 validated risk loci have been described to date (highly penetrating, moderately penetrating and low-penetrating genetic variants), which may explain 35–40% of the increased familial risk [1–14]. However, this also means that 60% of the increased familial risk cannot be explained by the mere genetic connections and it may still be some time until the interaction between genes or between genes and the environment can be connected in a usable way for the patient.

Nonetheless, the use of genetic and non-genetic risk information is more advanced than ever. There are some studies which attempt to decode the gene-gene interaction on the one hand and the gene-environment interaction on the other hand [15–29]. The two analyses which can most likely be used in clinical practice for patients are the use of as many risk variants as possible in order to define risk groups for patients with them [24, 30–32]. An example for practical implementation is shown in Figs. 1 and 2. These present that the 10% of 60-year-old women with the highest risk of at least 10% will develop hormone-receptor-positive breast cancer in the next 10 years. For the hormone-receptor-negative patients, the prediction is significantly reduced. Here it can be predicted for the 1% of women with the highest risk that they will develop a hormone-receptor-negative breast cancer with a probability of at least 1% [30].

The prediction could be optimised even further in combination with other risk factors, such as the analysis of mammographic density. In a large study in which 77 risk variants and the mammographic density were analysed, it was not able to be shown that the genetic variants which were responsible for the breast cancer risk could also explain the varying mammographic density. This means that both factors predict the risk independently of each other [15]. For the mammographic density, it is also known that it correlates with molecular characteristics of the breast cancer.

ZUSAMMENFASSUNG


This individualised assessment of risk factors may facilitate individualised early detection.

For women with a BRCA1 mutation, entirely new options for prevention potentially open up. The great significance of the RANKL/RANK pathway in women with a BRCA1 mutation has been known for some time [35–37]. A study on patients with BRCA1 mutations receiving the anti-RANKL antibody denosumab was therefore already started on this basis. A total of 2918 patients who carry mutations are to be randomised. Recruitment began in July 2017 [38]. The study design is shown in Fig. 3.
Early HER2-positive Breast Cancer

Neoadjuvant experiences with anti-HER2 therapies

In the neoadjuvant therapy situation, combination therapy with chemotherapy + trastuzumab + pertuzumab is approved and results in rates for pathological complete remission (pCR) of approx. 40–50% [39, 40]. The antibody-toxin conjugate (ADC) trastuzumab-emtansine (T-DM1) was able to demonstrate significant advantages for progression-free survival (PFS) and overall survival (OS) in a metastatic situation on the one hand [41] and recently also significant advantages for disease-free survival (DFS) in the post-neoadjuvant situation [42]. This raises the question of whether neoadjuvant therapy with T-DM1, for example, without classical chemotherapy but in combination with pertuzumab, provides an advantage for the patients. This issue was investigated within the scope of the neoadjuvant KRISTINE study. The KRISTINE study is a randomised, two-arm, open phase 3 study which compared 6 cycles of neoadjuvant therapy with docetaxel and carboplatin in combination with trastuzumab and pertuzumab (n = 223) with the alternative with 6 cycles of T-DM1 and pertuzumab (n = 221). Postoperatively the patients in the chemotherapy arm received 12 cycles of pertuzumab and trastuzumab, the patients in the T-DM1 arm received 12 cycles of T-DM1 and pertuzumab. For the patients in the T-DM1 arm who did not achieve pCR, adjuvant chemotherapy was recommended. The pCR rates (44.4 vs. 55.7% [p = 0.016]) in favour of the chemotherapy arm had already been published two years ago [43]. Currently, the secondary endpoints of disease-free survival (DFS) and invasive disease-free survival (iDFS) were reported after a median follow-up observation period of 37 months. In the DFS, a significant difference was seen in favour of the T-DM1 arm (hazard ratio [HR]: 2.61; 95% CI: 1.36–4.98), whereby this was triggered primarily by the 15 patients who suffered progression in the neoadjuvant therapy. In the chemotherapy arm, no progression during the neoadjuvant therapy was observed. In 12 of these 15 patients, a heterogeneous HER2 diagnosis was noted which may have contributed to this result. By contrast, the iDFS was comparable (HR = 1.11; 95% CI 0.52–2.40). To understand this, it must be mentioned that the DFS was calculated after randomisation but the iDFS was calculated after surgery and thus the 15 patients with progression in the neoadjuvant situation, as listed above, did not influence the DFS and iDFS [44]. The results of the KRISTINE study certainly generate hypotheses, yet they indicate that a loss of efficacy through de-escalation may be able to be compensated with a therapy modification controlled by the biomarker “response”.

De-escalation in anti-HER2-targeted therapies

The large number of drugs for the treatment of HER2-positive breast cancer represent the basis for considering a de-escalation of the therapies with regard to the duration of a therapy as well as the reduction of conventional chemotherapy. A new study regarding this issue was recently presented, the PREDIX study [45]. In this Swedish phase 3 study, patients were randomised either in the standard arm (103 patients; 6 × docetaxel, trastuzumab, pertuzumab → breast surgery → 2 × EG) or in the experimental arm (99 patients; 6 × trastuzumab-emtansine (T-DM1) → breast surgery → 4 × EG). After EC therapy, both arms received 11 × trastuzumab s.c. pCR was identified in the standard arm in 47% and in the experimental arms in 45% of the treated patients. In the hormone-receptor-negative patients, the rate was 67 and 59% and in the hormone-receptor-positive patients, the rate was 36% in both arms. No differences were significant. The known adverse effects of the drugs used were seen and here it could be noted that milder as well as serious adverse effects were found more rarely in the experimental arm [45]. Yet whether the ADC T-DM1 actually represents an effective option for treating breast cancer in a targeted manner and with few adverse effects must be seen in the connection with other studies. However, strategies must still be found to identify those patients who are predestined for such de-escalating therapy by using molecular, genetic, or imaging markers.
Benefits of a stratified, post-neoadjuvant therapy in HER2-positive breast cancer

Neoadjuvant systemic therapy permits in vivo sensitivity testing in addition to a reduction in surgical morbidity (more breast conservation, fewer axillary lymphadenectomies) [46–48]. Based on the effect of the neoadjuvant systemic therapy on the primary tumour, its effect on the long-term prognosis can be estimated [49,50].

Patients with HER2-positive breast cancer who did not achieve any pathological complete remission in the breast and axilla on neoadjuvant systemic therapy (pCR, ypT0/is ypN0) have an increased risk of recurrence and mortality [51–53]. The phase 3 KATHERINE study included 1486 patients with primary HER2-positive breast cancer who had not achieved pCR following neoadjuvant standard therapy with at least one taxane and trastuzumab for at least 9 weeks. On a randomised basis, they postoperatively received either T-DM1 (3.6 mg/kg) or trastuzumab (6 mg/kg) every 3 weeks for 14 cycles. With a median follow-up period of 41 months, the switch to T-DM1 significantly improved the invasive disease-free survival after 3 years (primary endpoint), from 77.0 to 88.3% (Δ 11.3%; HR 0.50; 95% CI: 0.39–0.64; p < 0.0001) as well as the metastasis-free survival (distant disease-free survival, DDFS) from 83.0 to 89.7% (Δ 6.7%; HR = 0.60; 95% CI: 0.45–0.79). This benefit was achieved at the expense of an increase in thrombopenia (grade ≥ 3 Δ + 5.7%), increased liver values (grade ≥ 3 Δ approx. + 1%) and polyneuropathy (grade ≥ 3 Δ + 1.4%) [42].

In addition, data from this study on quality of life were recently presented [54]. They were collected with the standardised and validated questionnaires European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and EORTC QLQ-Breast Cancer Module 23 (QLQ-BR23) during randomisation, on the first day of the 5th and 11th cycle, within 30 days after ending the study medication and after 6 and 12 months of follow-up observation. Overall, 612 (82%) and 640 (86%) patients in the trastuzumab and T-DM1 arms respectively were included in the assessment for whom quality-of-life parameters were surveyed at least one additional time point, in addition to the baseline survey. The questionnaires after 6 and 12 months of follow-up observation were also available from more than 70% of the patients in both study arms. The slightly increased rate of adverse effects on T-DM1 in comparison to trastuzumab (all grades 99 vs. 93%; grade ≥ 3 26 vs. 15%) had only a minimal and transient influence on patients’ quality of life. The mean value changes as compared to the baseline values were comparable and small in both treatment arms. On average, in both arms, no clinically significant worsening in the functional and symptom parameters was measured. Numerically, somewhat more patients in the T-DM1 arm than in the trastuzumab arm indicated a clinically significant worsening of individual quality-of-life parameters at individual points in time. However, these differences disappeared after 6 months of follow-up observation.

The data on quality of life thus confirm the superior efficacy of T-DM1 in comparison to trastuzumab in patients with HER2-positive breast cancer and invasive residual tumour following neoadjuvant chemo- and anti-HER2 therapy.

Early Hormone-Receptor-Positive Breast Cancer

With regard to the adjuvant therapy of patients with a hormone-receptor-positive breast cancer, the duration, choice, and sequence of aromatase inhibitors (AI) or tamoxifen depend in particular on the menopause status, tolerance, and risk of recurrence. Another intensively discussed topic is expanded adjuvant endocrine therapy (years 5–10 or even beyond). In accordance with the recommendations of the AGO Breast Cancer committee, this is recommended in the first 5 years only in the case of higher risk with concomitantly good tolerance [55,56]. In premenopausal women, the expanded therapy was administered with a total of 10 years of tamoxifen according to the data of the ATLAS study [57]. In the postmenopausal situation, a switch can be made to an AI. In patients who had started with an AI, the data according to the ABCSG-16 study to date suggest an extension to 7 instead of 10 years [58].

The exact duration of the expanded endocrine therapy with aromatase inhibitors following an initial sequence therapy of tamoxifen followed by an aromatase inhibitor is additionally the focus of further investigations: In a prospective randomised study (NCT01064635) by Del Mastro et al. [59], various durations of treatment with an endocrine therapy with AI after tamoxifen were investigated. The collective consisted of postmenopausal patients with hormone-receptor-positive, primary breast cancer who had adjuvantly received 2–3 years of tamoxifen. Randomisation into two groups was performed: 2–3 years of further therapy with letrozole or 5 years of letrozole. The primary endpoint was the DFS. A total of 2056 patients were included in the study. Of these patients, 1030 received the brief therapy with letrozole for 2–3 years and 1026 patients received the longer, 5-year therapy. The baseline characteristics, in particular, age and node status (node-negative patients: 56 vs. 56%; (neo-)adjuvant chemotherapy: 53.4 vs. 54.1%) were homogeneously distributed in both groups. The median follow-up period was 10 years (8.6–11.4). The 8-year DFS rate was 80% (95% CI 77.3–82.7) and 85% (95% CI 82.9–87.6) in the case of brief or prolonged administration (HR: 0.82; 95% CI 0.68–0.98; p = 0.031). This significant advantage did not change by adjusting the node status, age, or grading. However, the rate of diagnosed osteoporosis was twice as high in the group with prolonged therapy: 81 (8.3%) versus 47 (4.8%), which makes the necessary benefit/risk assessment clear. Therefore the further identification of the collective which actually benefits from expanded therapy is necessary for clinical practice. However, there is currently no sufficiently validated biomarker for a possible prediction [55]. Within the framework of a translational question from the aTTom study, it was now investigated whether the Breast Cancer Index (BCI) can be used for the individual therapeutic decision regarding expanded endocrine therapy [60]. Within the framework of the aTTom study – similarly to the ATLAS study – 6956 patients after at least four years of tamoxifen therapy were randomised to stop therapy or continue with another 5 years of tamoxifen. After an 8.9-year follow-up, the prolonged tamoxifen therapy demonstrated a benefit for the entire group with regard to the disease-free survival with an HR of 0.86 (95% CI 0.77–0.96
The BCI is a gene expression test consisting of a signature of 11 genes which contains 5 genes for tumour proliferation as well as 2 genes of the oestrogen signalling pathway. The BCI provides information on the cumulative prognosis of years (p = 0.006). The BCI is a gene expression test consisting of a significant advantage through the 10-year therapy was able to be demonstrated (HR = 0.88; 95% CI: 0.65–1.18 and HR = 1.07; 95% CI: 0.69–1.65), an advantage for patients with a high BCI result was seen with an HR of 0.35 (95% CI: 0.15–0.86). The absolute difference in DFS through the extended therapy was 4.7% in node-positive patients (p = 0.388), −0.2% (p = 0.768) at a low BCI score, and 10.2% (p = 0.027) at a high BCI score. Even after adjusting age, tumour size, grading, ER and PR status, a significant interaction between BCI and therapy was seen (p = 0.01). The authors concluded that the BCI gene expression test is predictive for the expanded endocrine therapy with 10 years of tamoxifen in node-positive patients.

With regard to the GIM4 study, a current discussion on the results [61] revealed that the expanded therapy with an AI beyond 5 years demonstrated only a minimal to no effect on the disease-free survival, however it substantially reduced secondary carcinomas. The advantages and disadvantages must still be discussed individually with the patient and a mutual therapeutic decision must be made. The high discontinuation rates after the 5th year must be taken into account here. The adherence or compliance here is 57.5% to a maximum of 85–90%, depending on the study. With regard to the Trans-aTTom study, it was discussed [61] that only the group of node-positive patients met the prespecified criteria for the analysis and thus no statement on the node-negative patients can be made. Even if there is now an option to avoid overtreatment, the results for the entire collective should be waited for and confirmed by another study with comparable therapy and length – only then will there be corresponding evidence. In addition, the benefit of the BCI test for patients with aromatase inhibitor therapy in the first 5 years remains open.

While BCI has not yet been broadly applied in clinical practice, data from a prospective, randomised study are available following the publication of the TAILORx study [62,63] which attempts to identify the hormone-receptor-positive patients who can definitively omit chemotherapy. Here the study showed that in patients under age 50, it is questionable as to whether chemotherapy can be omitted [62]. In the current discussion [61], it must be borne in mind that caution is called for in the interaction between age and risk score (RS) within the scope of the TAILORx study, since this is an exploratory analysis: The TAILORx study showed that endocrine therapy is not inferior to chemotherapy in the case of a recurrence score between 11 and 25 in patients over age 50 and between 11 and 16 in patients under age 50. The addition of clinical-pathological parameters should also allow an exemplary answer to the question as to whether the prognostic information (low risk – tumour ≤ 3 cm and G1, ≤ 2 cm and G2, or ≤ 1 cm and G3) or high risk (if the criteria of the low-risk group are not met) [64] can be further improved. Through the addition of these parameters, the group of patients under age 50 with a recurrence score between 16 and 20 can be further differentiated: absolute risk reduction with chemotherapy in the case of an RS of 16–20 (n = 923): −0.2% (standard error [SE] ± 2.1%) for low risk vs. 6.5% (SE ± 4.9%) for high risk. This confirms once again that the meaningfulness of gene expression analyses should be considered in the context of clinical-pathological parameters. An intriguing question remains regarding whether women ≤ 50 years could possibly benefit from ovarian suppression with tamoxifen/AI instead of chemotherapy.

In summary, instruments are needed which integrate clinical and pathological factors as well as biomarkers from tumour tissue and blood and additional patient factors in order to ensure truly individualised therapeutic approaches.

With the introduction of CDK4/6 inhibitors in patients with hormone-receptor-positive breast cancer (summarised in [65]), in particular also because 2 studies showed a significant overall survival advantage [66–68], large adjuvant therapy studies have been started for all 3 approved CDK4/6 inhibitors. The study results are still all pending. However, similar to the case in the above studies, adherence is no doubt an important topic [69,70] which must be better understood and which could possibly be improved through digital patient support [71–74] or special communication programmes.

**Early, Triple-Negative Breast Cancer**

Patients with early, triple-negative breast cancer have the worst prognosis of all molecular subtypes, now that patients with a HER2-positive finding benefit so clearly from trastuzumab therapy that, by now, they represent a prognostically favourable group [75]. Since there are no points of attack for targeted therapy, chemotherapy is the only standard therapeutic option to date. However, a relatively high proportion of patients also responded to chemotherapy. Following neoadjuvant chemotherapy, approx. 40–50% of the TNBC patients achieve pCR. For these patients, it is known that they also have an excellent prognosis [32,76–83]. In the search for new targets for these patients, more and more about the biology of this breast cancer subtype is being understood. Some of these characteristics could soon help to better treat this form of breast cancer also in a non-metastatic primary situation.

Chemotherapy combinations containing platinum are increasingly being used in the case of this tumour biology, as a result of which the rate of pathological complete remissions (pCR) has been able to be significantly increased in the neoadjuvant setting. However, its effect on the long-term prognosis has not been definitively explained to date [79,84–87]. Here other biomarkers (apart from the triple-negative receptor status) could be helpful in identifying those patients who benefit the most from chemotherapy containing platinum. In view of this, the HRD score (HRD = Homologous Recombination Deficiency) is a marker of interest. Homologous recombination is necessary, among other things, to repair double-strand breaks, such as those caused by platinum derivatives [88]. Since **BRCA1** and **BRCA2** play an impor-
tant role in the repair of double-strand breaks, BRCA1/2-associated carcinomas are characterised by an elevated HRD score (Fig. 4). Patients with a BRCA1/2 germ line mutation (gBRCA) also more frequently develop triple-negative breast cancer and patients with a triple-negative breast cancer far more frequently have a BRCA1/2 mutation [1, 3, 10, 80, 83]. Accordingly, in sporadic triple-negative tumours, there are frequently changes which resemble the pathological and molecular genetic characteristics of gBRCA mutated carcinomas (so-called “BRCaness”), and also increased HRD-positive tumours [89].

In the recently presented TRCBC-030 study, the extent to which the HRD score is associated with the response to neoadjuvant therapy either with paclitaxel or cisplatin was investigated [90]. Of 140 patients with triple-negative primary breast cancer (stage II–III, gBRCA-negative) randomised to 4 × cisplatin 75 mg/m², q3w vs. 12 × paclitaxel 80 mg/m², q1w, 68/95 (71.6%) patients had a usable test result (Myriad Genetics) of “HRD-positive” (score > 33). 15% of the patients in the carboplatin arm and 13% of the patients in the paclitaxel arm had a pCR. In neither of the two arms was a connection between therapeutic response and HRD positivity seen. Similar data were already demonstrated within the framework of the German GeparSixto study. In this study, the HRD positivity as well as the presence of a gBRCA1 mutation or gBRCA2 mutation were confirmed as markers for an overall better response to neoadjuvant systemic therapy, however they were not predictive for an explicit benefit through the addition of carboplatin [80, 91]. In routine clinical practice as well, similar effects with regard to platinum and gBRCA mutations in the neoadjuvant situation have been described [92].

Another recently presented study on the predictive effect of the defective homologous recombination is the GeparOla study in which the effect of PARP inhibition with olaparib on pCR was investigated [93]. Only HRD-positive or BRCA1/2-positive (somatic or germ line mutation) women with early HER2-negative breast cancer were included. The patients received either 12 × paclitaxel (80 mg/m²) weekly + olaparib 2 × daily (PO) or 12 × paclitaxel (80 mg/m²) weekly + carboplatin (AUC2) weekly (PCb), each followed by EC (90/600 mg/m², q14d or q21d). The primary study endpoint was not the comparison of both arms, but rather the question of whether a pCR rate of at least 55% can be reached in HRD-positive patients and whether in doing so, carboplatin can be omitted, in view of the increased adverse effects. However, there should be a focus on potential long-term toxicities of PARP inhibition, and not only the pCR but also the influence of the long-term prognosis should be taken into account.

Checkpoint inhibition in early triple-negative breast cancer

It is already known that in patients with triple-negative breast cancer, an infiltration with lymphocytes (TILs) is associated with a higher pCR rate and a better prognosis [77, 94]. In the first lines of therapy in advanced breast cancer in the case of positivity of the immune cells in the tumour for PD-L1, a significant survival advantage was able to be demonstrated in the case of therapy with the anti-PD-L1 antibody atezolizumab and nab-paclitaxel versus therapy with nab-paclitaxel alone [95]. There are now the first indications of the efficacy from the neoadjuvant situation. In a press release, it was reported [96] that the Keynote-522 study [97] is positive with regard to one of the two primary endpoints (pCR). This means that the addition of the anti-PD-1 antibody pembrolizumab to chemotherapy was able to significantly increase the rate of pCR. 1174 triple-negative patients were recruited in the study [98].

Schütz F et al. Update Breast Cancer... Geburtsh Frauenheilk 2019; 79: 1079–1089
Outlook

With the introduction of the multigene tests in hormone-receptor-positive patients and the success of T-DM1 after failure of neoadjuvant chemotherapy with anti-HER2 combinations, significant advancements have been achieved in some patients with early breast cancer. The assessments of therapeutic success from the metastatic situation (CDK4/6 inhibitors) are still ongoing. It can also be expected to be assessed for therapy programmes, as with the PI3K inhibitor alpelisib, to be created. For triple-negative breast cancer, there is in fact an increasing understanding of the tumour PI3K inhibitor alpelisib, to be created. For triple-negative breast cancer, the assessments of therapeutic success from neoadjuvant chemotherapy with anti-HER2 combinations, significant.

Acknowledgements

This work was developed in part as a result of support from Hexal and the PRAEGNANT network which is supported by Pfizer, Celgene, Daiichi Sankyo, Roche, Merrimack, Eisai, AstraZeneca, Hexal and Novartis. None of the companies played a role in the drafting of this manuscript. The authors alone are responsible for the content of the manuscript.

Conflict of Interest

A.D.H. received speaker and consultancy honoraria from AstraZeneca, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Teva, Tesaro, Daiichi Sankyo, Hexal and Pfizer. F.O. received speaker and consultancy honoraria from Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Chugai, Celgene, Cellex, Eisai, Gilead, Hexal, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, Riems, Roche, Tesaro, Teva. H.-C.K. received honoraria from Carl Zeiss meditec, Teva, Theracion, Novartis, Amgen, AstraZeneca, Pfizer, Janssen-Cilag, GSK, LIV Pharma, Roche and Genomic Health. P.A.F. received honoraria from Novartis, Pfizer, Roche, Amgen, Celgene, Daiichi Sankyo, AstraZeneca, MSD, Eisai, Puma and Teva. His institution conducts research with funding from Novartis and Biontech. M.W. received speakers honoraria and consultation fees from Novartis, Amgen, Celgene, Roche, Genentech, AstraZeneca, and Pfizer. H.T. received honoraria from Novartis, Roche, Celgene and Pfizer, and travel support from Roche, Celgene and Pfizer. J.E. received honoraria from AstraZeneca, Roche, Celgene, Novartis, Lilly, Pfizer, Pierre Fabre, Teva and travel support from Celgene, Pfizer, Teva and Pierre Fabre. M.P.L. has participated on advisory boards for AstraZeneca, MSD, Novartis, Pfizer, Eisai, Genomic Health and Roche and has received honoraria for lectures from MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health, AstraZeneca, medac and Eisai. V.M. received speaker honoraria from Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Pfizer, Novartis, Roche, Teva, Janssen-Cilag and consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, Novartis, MSD, Daiichi Sankyo and Eisai, Lilly, Tesaro and Nektar. E.B. received honoraria from Novartis, Riems, Pfizer, Hexal, Amgen, and onkowissen.de for consulting, clinical research management or medical education activities. A.S. received honoraria from Roche, Celgene, AstraZeneca, Novartis, Pfizer, Zuckscherdt Verlag GmbH, Georg Thieme Verlag, Aurikamed GmbH, MCI Deutschland GmbH, bsh medical communications GmbH and promedics GmbH. W.J. received honoraria and research grants from Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, Sanofi, Daiichi Sankyo, Tesaro. F.S. participated on advisory boards for Novartis, Lilly, Amgen and Roche and received honoraria for lectures from Roche, AstraZeneca, MSD, Novartis and Pfizer. A.W. participated on advisory boards for Novartis, Lilly, Amgen, Pfizer, Roche, Tesaro, Eisai and received honoraria for lectures from Novartis, Pfizer, Aurikamed, Roche, Celgene. D.L. received honorarium from Amgen, AstraZeneca, Celgene, Lilly, Loreal, MSD, Novartis, Pfizer, Tesaro, Teva. T.N.F. has participated on advisory boards for Amgen, Daiichi Sankyo, Novartis, Pfizer, and Roche and has received honoraria for lectures from Amgen, Celgene, Daiichi Sankyo, Roche, Novartis and Pfizer.

References


[93] Fasching P, Jackisch C, Rhiem K et al. GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD). J Clin Oncol 2019; 37 (Suppl.): Abstr. 506


